A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
References to “Plus Therapeutics,” the “Company,” “we,” “us” and “our” refer to Plus Therapeutics, Inc. References to “Notes” refer to the Notes to Financial Statements included herein (refer to Item 8). Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (“CNS”) cancers. Our novel radioactive drug formulations and medical devices and therapeutic candidates are designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 5.3M | - | - | - | - | - |
| Net Income | -21M | -13M | -13M | -20M | -8.2M | -11M |
| EPS | $-0.96 | $-2.34 | $-4.24 | $-11.58 | $-27.90 | $-124.05 |
| Free Cash Flow | -16M | -11M | -13M | -13M | -8.5M | -6.0M |
| ROIC | -56.9% | -175.0% | -92.4% | -65.2% | -88.0% | -21.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.81 | -8.85 | 1.09 | 6.27 | 19.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -13M | -15M | -13M | -20M | -9.6M | -3.7M |
| Operating Margin | -255.9% | - | - | - | - | - |
| ROE | -407.1% | - | - | -314.6% | -271.9% | -358.4% |
| Shares Outstanding | 137M | 17M | 17M | 4M | 1M | 0M |
PLUS THERAPEUTICS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
PLUS THERAPEUTICS, INC. (PSTV) has a 5-year average return on invested capital (ROIC) of -88.4%. This is below average and may indicate limited pricing power.
PLUS THERAPEUTICS, INC. (PSTV) has a market capitalization of $746M. It is classified as a small-cap stock.
PLUS THERAPEUTICS, INC. (PSTV) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.05%.
PLUS THERAPEUTICS, INC. (PSTV) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
PLUS THERAPEUTICS, INC. (PSTV) generated $-11 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PLUS THERAPEUTICS, INC. (PSTV) reported earnings per share (EPS) of $-2.34 in its most recent fiscal year.
The Ledger Terminal provides 16 years of financial data for PLUS THERAPEUTICS, INC. (PSTV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PLUS THERAPEUTICS, INC. (PSTV) has a book value per share of $-0.53, based on its most recent annual SEC filing.